Unexpected finding points to potential way to stop macular degeneration
In a major step forward in the battle against macular degeneration, the leading cause of vision loss among the elderly, researchers at the University of Virginia School of Medicine have discovered a critical trigger for the damaging inflammation that ultimately robs millions of their sight. The finding may allow doctors to halt the inflammation early on, potentially saving patients from blindness.
“Almost 200 million people in the world have macular degeneration. If macular degeneration were a country, it would be the eighth most populated nation in the world. That’s how large a problem this is,” said Jayakrishna Ambati, MD, vice chairman for research of UVA’s Department of Ophthalmology and the founding director of UVA’s Center for Advanced Vision Science. “For the first time, we know in macular degeneration what is one of the very first events that triggers the system to get alarmed and start, to use an anthropomorphic term, hyperventilating. This overdrive of inflammation is what ultimately damages cells, and so, potentially, we have a way of interfering very early in the process.”
Potential New Treatment for Macular Degeneration
Ambati and Nagaraj Kerur, PhD, assistant professor in the Department of Ophthalmology, and their laboratories have determined that the culprit is an enzyme called cGAS. The enzyme plays an important role in the body’s immune response to infections by detecting foreign DNA. But the molecule’s newly identified role in the “dry” form of age-related macular degeneration comes as wholly unexpected.
“It’s really surprising that in macular degeneration, which, as far as we know, has nothing to do with viruses or bacteria, that cGAS is activated, and that this alarm system is turned on,” Ambati said. “This is what leads to the killing of the cells in the retina, and, ultimately, vision loss.”
The researchers noted that cGAS may be an alarm not just for pathogens but for other harmful problems that warrant responses from the immune system. The enzyme may also play important roles in conditions such as diabetes, lupus and obesity, and researchers already are working to create drugs that could inhibit its function. “Because the target we’re talking about is an enzyme, we could develop small molecules that could block it,” Kerur said. “There are many drugs already on the market that target specific enzymes, such as the statins [which are used to lower cholesterol levels.]”
The promising new lead comes as good news for researchers seeking to develop new treatments for dry macular degeneration, as clinical trials in recent years have come to dead end after dead end.
The UVA researchers expect the development of a drug to inhibit cGAS will take several years, and that drug would then need to go through extensive testing to determine its safety and effectiveness for combating macular degeneration.
The researchers also hope to develop a way to detect the levels of the enzyme in patients’ eyes. That would let them determine when best to administer a treatment that blocks cGAS. “If they have high levels of this enzyme in their eye, they might be a wonderful candidate for this sort of treatment,” Ambati said. “This is really precision medicine at the single-molecule level.”
The Latest on: Macular degeneration
- New ways to prove efficacy of emerging treatments for macular diseaseson June 3, 2020 at 5:21 am
Stargardt disease is an inherited eye disease. Its onset is typically in adolescence and it is among the leading causes of blindness in this age group. Symptoms range from severe loss of sharp vision ...
- Bedford biomedical firm receives $2 million to begin macular degeneration trialson June 3, 2020 at 4:51 am
Nanoscope Technologies has gotten a $2 million award from the National Eye Institute for a gene therapy treatment for macular degeneration. The ...
- Prevalence of Retinal Diseases and Associated Risk Factors in an African Population From Mwanza, Tanzaniaon June 2, 2020 at 5:16 pm
BACKGROUND AND OBJECTIVE:To determine the prevalence of retinal disease among a population in Mwanza, Tanzania, and to identify relevant risk factors for retinal disorders in this cohort.PATIENTS AND ...
- Twenty-Year Incidence of Macular Telangiectasia Type 2 and Associated Systemic Comorbidities in Olmsted County, Minnesotaon June 2, 2020 at 5:06 pm
BACKGROUND AND OBJECTIVE:To identify the incidence and associated systemic and ocular risk factors of macular telangiectasia (MacTel) type 2 using a population-based study.PATIENTS AND METHODS:In this ...
- Global Age-related Macular Degeneration Market 2020 Industry Size, Cost Structure Analysis, Growth, Share and Opportunities and Forecast to 2026on June 2, 2020 at 5:07 am
Global “ Age-related Macular Degeneration Market ” report presents an in-depth assessment of the Age-related Macular Degeneration market dynamics, opportunities, future roadmap, competitive landscape ...
- Wet Age-Related Macular Degeneration: Treatment Advances to Reduce the Injection Burdenon May 28, 2020 at 5:00 pm
The burden of age-related macular degeneration (AMD), a leading cause of vision loss in the elderly population, is poised to increase dramatically as the baby boomer generation ages. Fortunately, the ...
- AI Systems Predict the Course of Macular Degenerationon May 27, 2020 at 11:33 am
Two new artificial intelligence algorithms can predict the development of age-related macular degeneration, researchers say.
- AI model predicts risk for age-related macular degenerationon May 27, 2020 at 10:46 am
A new artificial intelligence algorithm can predict risk for age-related macular degeneration (AMD), according to a study published in the April issue of Translational Vision Science and Technology.
- Port Delivery System With Ranibizumab Shows Positive Phase III Results in Neovascular Age-Related Macular Degenerationon May 26, 2020 at 10:31 pm
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from the Phase III Archway study, evaluat ...
- Roche's Port Delivery System with ranibizumab shows positive phase III results in neovascular age-related macular degenerationon May 26, 2020 at 10:00 pm
Port Delivery System with ranibizumab (PDS) is a permanent refillable eye implant that continuously delivers ranibizumab over a period of months, potentially reducing ...
via Google News and Bing News